ESMO25: The importance of personalisation, with Bayer’s Dr Nicoletta Brega and Christine Roth

Oncology
Interview at ESMO 2025 with Nicoletta Brega and Christine Roth from Bayer

At this year’s European Society for Medical Oncology (ESMO) Congress, Bayer had multiple data presentations, from the Phase 3 ARASAFE trial and pivotal ARANOTE trial evaluating darolutamide in metastatic hormone-sensitive prostate cancer, to the AlphaBet trial  and global REASSURE study of radium-223 in metastatic castration-resistant prostate cancer.

However, it was the late-breaking Phase 1/2 data from the SOHO-01 study of sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer that pharmaphorum spoke about with Dr Nicoletta Brega, VP and Global Development Lead of Clinical Precision Oncology at Bayer, and Christine Roth, Head of Global Product Strategy and Commercialisation at Bayer, onsite in Berlin.

Brega and Roth discuss the data and evolving treatment landscape, as well as Bayer’s own oncology portfolio and innovation strategy in terms of the shift to a greater focus on personalisation.

Watch this and other conversations from ESMO 2025 here.